drugset
Drugs / Multiple Antigens Specific Cellular Therapy
last change Dec 2019 re-read 3 minutes ago

Multiple Antigens Specific Cellular Therapy

also known as MASCT

Cell therapy

Developed for
hepatocellular carcinoma
Investigated by
Beijing 302 Hospital · Fujian Cancer Hospital · HRYZ Biotech Co. · Nanfang Hospital, Southern Medical University · Sun Yat-sen University · Third Affiliated Hospital, Sun Yat-Sen University

Trials 1

today NCT02026362 · Ph 1/2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02026362 Jul 2013 → Jul 2017 hepatocellular carcinoma HRYZ Biotech Co. Suspended No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Multiple Antigens Specific Cellular Therapy “MASCT:Multiple Antigens Specific Cellular Therapy” NCT02026362 ↗
Known as MASCT ClinicalTrials.gov intervention name — accepted as the source's own label NCT02026362 ↗
Modality Cell therapy “autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells” NCT02026362 ↗